Psoriasis risk after beta-blocker exposure: Description of a pharmacovigilance signal.

Brahim AzzouzApolline De GuizelinAude LambertAudrey FresseAurore MorelThierry Trenque

Published in: British journal of clinical pharmacology (2022)

We highlighted a statistically significant disproportionality which constitutes a pharmacovigilance signal. Psoriasis risk with BBs is a class effect. Increasing surveillance during the first year of BB exposure is needed.

Keyphrases

adverse drug
public health
growth factor
angiotensin ii